Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
Seoul, Korea, Aug 3: — Mezzion Pharma Co., Ltd. today announced positive results from a new in vivo study of udenafil, a novel phosphodiesterase type 5 (PDE5) inhibitor, in autosomal dominant polycystic kidney disease (ADPKD). In a preclinical ADPKD model, udenafil reduced kidney cyst burden and blood urea nitrogen (BUN), a blood marker linked […]
Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD Read More »